1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Product Innovation / Development Trends

4. Market Background

    4.1. Macro-Economic Factors

    4.2. Forecast Factors – Relevance & Impact

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunity Analysis

5. COVID19 Crisis Analysis

    5.1. Current COVID19 Statistics and Probable Future Impact

    5.2. COVID-19 Impact on GDP

    5.3. COVID-19 Impact of Market

6. Market Context

    6.1. Product Development

    6.2. Product Adoption / Usage Analysis

    6.3. Regulatory Scenario

    6.4. Pipeline Assessment

7. Global Market Value Analysis 2018-2022 and Forecast, 2023-2033

    7.1. Historical Market Value (US$ Mn) Analysis, 2018-2022

    7.2. Current and Future Market Value (US$ Mn) Projections, 2023-2033

        7.2.1. Y-o-Y Growth Trend Analysis

        7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2018-2022 and Forecast 2023-2033, by Distributional Channel

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Distributional Channel, 2018-2022

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distributional Channel, 2023-2033

        8.3.1. Hospital pharmacies

        8.3.2. Retail pharmacies

        8.3.3. Mail-Order pharmacies

    8.4. Market Attractiveness Analysis By Distributional Channel

9. Global Market Analysis 2018-2022 and Forecast 2023-2033, by Region

    9.1. Introduction

    9.2. Historical Market Size (US$ Mn) Analysis By Region, 2018-2022

    9.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2023-2033

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. East Asia

        9.3.5. South Asia

        9.3.6. Oceania

        9.3.7. Middle East and Africa (MEA)

    9.4. Market Attractiveness Analysis By Region

10. North America Market Analysis 2018-2022 and Forecast 2023-2033

    10.1. Introduction

    10.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    10.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        10.3.1. By Country

            10.3.1.1. U.S.

            10.3.1.2. Canada

        10.3.2. By Application

        10.3.3. By Distributional Channel

    10.4. Market Attractiveness Analysis

    10.5. Key Market Participants – Intensity Mapping

    10.6. Drivers and Restraints – Impact Analysis

11. Latin America Market Analysis 2018-2022 and Forecast 2023-2033

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        11.3.1. By Country

            11.3.1.1. Brazil

            11.3.1.2. Mexico

            11.3.1.3. Argentina

            11.3.1.4. Rest of Latin America

        11.3.2. By Application

        11.3.3. By Distributional Channel

    11.4. Market Attractiveness Analysis

    11.5. Key Market Participants – Intensity Mapping

    11.6. Drivers and Restraints – Impact Analysis

12. Europe Market Analysis 2018-2022 and Forecast 2023-2033

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        12.3.1. By Country

            12.3.1.1. Germany

            12.3.1.2. Italy

            12.3.1.3. France

            12.3.1.4. U.K.

            12.3.1.5. Spain

            12.3.1.6. Russia

            12.3.1.7. Rest of Europe

        12.3.2. By Application

        12.3.3. By Distributional Channel

    12.4. Market Attractiveness Analysis

    12.5. Key Market Participants – Intensity Mapping

    12.6. Drivers and Restraints – Impact Analysis

13. South Asia Market Analysis 2018-2022 and Forecast 2023-2033

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        13.3.1. By Country

            13.3.1.1. India

            13.3.1.2. Thailand

            13.3.1.3. Indonesia

            13.3.1.4. Malaysia

            13.3.1.5. Rest of South Asia

        13.3.2. By Application

        13.3.3. By Distributional Channel

    13.4. Market Attractiveness Analysis

    13.5. Key Market Participants – Intensity Mapping

    13.6. Drivers and Restraints – Impact Analysis

14. East Asia Market Analysis 2018-2022 and Forecast 2023-2033

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        14.3.1. By Country

            14.3.1.1. China

            14.3.1.2. Japan

            14.3.1.3. South Korea

        14.3.2. By Application

        14.3.3. By Distributional Channel

    14.4. Market Attractiveness Analysis

    14.5. Key Market Participants – Intensity Mapping

    14.6. Drivers and Restraints – Impact Analysis

15. Oceania Market Analysis 2018-2022 and Forecast 2023-2033

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        15.3.1. By Country

            15.3.1.1. Australia

            15.3.1.2. New Zealand

        15.3.2. By Application

        15.3.3. By Distributional Channel

    15.4. Market Attractiveness Analysis

    15.5. Key Market Participants – Intensity Mapping

    15.6. Drivers and Restraints – Impact Analysis

16. Middle East and Africa Market Analysis 2018-2022 and Forecast 2023-2033

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        16.3.1. By Country

            16.3.1.1. GCC Countries

            16.3.1.2. South Africa

            16.3.1.3. Rest of Middle East and Africa

        16.3.2. By Application

        16.3.3. By Distributional Channel

    16.4. Market Attractiveness Analysis

    16.5. Key Market Participants – Intensity Mapping

    16.6. Drivers and Restraints – Impact Analysis

17. Market Structure Analysis

    17.1. Market Analysis by Tier of Companies

    17.2. Market Concentration

    17.3. Market Share Analysis of Top Players

    17.4. Market Presence Analysis

        17.4.1. By Regional footprint of Players

        17.4.2. Product foot print by Players

        17.4.3. Channel Foot Print by Players

18. Competition Analysis

    18.1. Competition Dashboard

    18.2. Competition Benchmarking

    18.3. Competition Deep Dive

        18.3.1. Mylan NV

            18.3.1.1. Overview

            18.3.1.2. Product Portfolio

            18.3.1.3. Analyst Commentary

            18.3.1.4. Key Financials

            18.3.1.5. Recent Developments

            18.3.1.6. Sales Footprint

            18.3.1.7. Strategy Overview

                18.3.1.7.1. Marketing Strategy

                18.3.1.7.2. Product Strategy

                18.3.1.7.3. Channel Strategy

        18.3.2. Novartis AG

            18.3.2.1. Overview

            18.3.2.2. Product Portfolio

            18.3.2.3. Analyst Commentary

            18.3.2.4. Key Financials

            18.3.2.5. Recent Developments

            18.3.2.6. Sales Footprint

            18.3.2.7. Strategy Overview

                18.3.2.7.1. Marketing Strategy

                18.3.2.7.2. Product Strategy

                18.3.2.7.3. Channel Strategy

        18.3.3. Coherus BioSciences

            18.3.3.1. Overview

            18.3.3.2. Product Portfolio

            18.3.3.3. Analyst Commentary

            18.3.3.4. Key Financials

            18.3.3.5. Recent Developments

            18.3.3.6. Sales Footprint

            18.3.3.7. Strategy Overview

                18.3.3.7.1. Marketing Strategy

                18.3.3.7.2. Product Strategy

                18.3.3.7.3. Channel Strategy

        18.3.4. Mundipharma International

            18.3.4.1. Overview

            18.3.4.2. Product Portfolio

            18.3.4.3. Analyst Commentary

            18.3.4.4. Key Financials

            18.3.4.5. Recent Developments

            18.3.4.6. Sales Footprint

            18.3.4.7. Strategy Overview

                18.3.4.7.1. Marketing Strategy

                18.3.4.7.2. Product Strategy

                18.3.4.7.3. Channel Strategy

        18.3.5. Biocon

            18.3.5.1. Overview

            18.3.5.2. Product Portfolio

            18.3.5.3. Analyst Commentary

            18.3.5.4. Key Financials

            18.3.5.5. Recent Developments

            18.3.5.6. Sales Footprint

            18.3.5.7. Strategy Overview

                18.3.5.7.1. Marketing Strategy

                18.3.5.7.2. Product Strategy

                18.3.5.7.3. Channel Strategy

        18.3.6. Intas Pharmaceuticals Ltd.

            18.3.6.1. Overview

            18.3.6.2. Product Portfolio

            18.3.6.3. Analyst Commentary

            18.3.6.4. Key Financials

            18.3.6.5. Recent Developments

            18.3.6.6. Sales Footprint

            18.3.6.7. Strategy Overview

                18.3.6.7.1. Marketing Strategy

                18.3.6.7.2. Product Strategy

                18.3.6.7.3. Channel Strategy

        18.3.7. Pfizer Inc.

            18.3.7.1. Overview

            18.3.7.2. Product Portfolio

            18.3.7.3. Analyst Commentary

            18.3.7.4. Key Financials

            18.3.7.5. Recent Developments

            18.3.7.6. Sales Footprint

            18.3.7.7. Strategy Overview

                18.3.7.7.1. Marketing Strategy

                18.3.7.7.2. Product Strategy

                18.3.7.7.3. Channel Strategy

        18.3.8. Dr Reddy’s Laboratories

            18.3.8.1. Overview

            18.3.8.2. Product Portfolio

            18.3.8.3. Analyst Commentary

            18.3.8.4. Key Financials

            18.3.8.5. Recent Developments

            18.3.8.6. Sales Footprint

            18.3.8.7. Strategy Overview

                18.3.8.7.1. Marketing Strategy

                18.3.8.7.2. Product Strategy

                18.3.8.7.3. Channel Strategy

        18.3.9. Zydus Cadila

            18.3.9.1. Overview

            18.3.9.2. Product Portfolio

            18.3.9.3. Analyst Commentary

            18.3.9.4. Key Financials

            18.3.9.5. Recent Developments

            18.3.9.6. Sales Footprint

            18.3.9.7. Strategy Overview

                18.3.9.7.1. Marketing Strategy

                18.3.9.7.2. Product Strategy

                18.3.9.7.3. Channel Strategy

        18.3.10. Apotex Inc.

            18.3.10.1. Overview

            18.3.10.2. Product Portfolio

            18.3.10.3. Analyst Commentary

            18.3.10.4. Key Financials

            18.3.10.5. Recent Developments

            18.3.10.6. Sales Footprint

            18.3.10.7. Strategy Overview

                18.3.10.7.1. Marketing Strategy

                18.3.10.7.2. Product Strategy

                18.3.10.7.3. Channel Strategy

        18.3.11. Emcure Pharmaceuticals Pvt Ltd.

            18.3.11.1. Overview

            18.3.11.2. Product Portfolio

            18.3.11.3. Analyst Commentary

            18.3.11.4. Key Financials

            18.3.11.5. Recent Developments

            18.3.11.6. Sales Footprint

            18.3.11.7. Strategy Overview

                18.3.11.7.1. Marketing Strategy

                18.3.11.7.2. Product Strategy

                18.3.11.7.3. Channel Strategy

        18.3.12. USV Private Limited

            18.3.12.1. Overview

            18.3.12.2. Product Portfolio

            18.3.12.3. Analyst Commentary

            18.3.12.4. Key Financials

            18.3.12.5. Recent Developments

            18.3.12.6. Sales Footprint

            18.3.12.7. Strategy Overview

                18.3.12.7.1. Marketing Strategy

                18.3.12.7.2. Product Strategy

                18.3.12.7.3. Channel Strategy

        18.3.13. Lupin

            18.3.13.1. Overview

            18.3.13.2. Product Portfolio

            18.3.13.3. Analyst Commentary

            18.3.13.4. Key Financials

            18.3.13.5. Recent Developments

            18.3.13.6. Sales Footprint

            18.3.13.7. Strategy Overview

                18.3.13.7.1. Marketing Strategy

                18.3.13.7.2. Product Strategy

                18.3.13.7.3. Channel Strategy

        18.3.14. Kashiv Biosciences

            18.3.14.1. Overview

            18.3.14.2. Product Portfolio

            18.3.14.3. Analyst Commentary

            18.3.14.4. Key Financials

            18.3.14.5. Recent Developments

            18.3.14.6. Sales Footprint

            18.3.14.7. Strategy Overview

                18.3.14.7.1. Marketing Strategy

                18.3.14.7.2. Product Strategy

                18.3.14.7.3. Channel Strategy

        18.3.15. Fresenius Kabi

            18.3.15.1. Overview

            18.3.15.2. Product Portfolio

            18.3.15.3. Analyst Commentary

            18.3.15.4. Key Financials

            18.3.15.5. Recent Developments

            18.3.15.6. Sales Footprint

            18.3.15.7. Strategy Overview

                18.3.15.7.1. Marketing Strategy

                18.3.15.7.2. Product Strategy

                18.3.15.7.3. Channel Strategy

        18.3.16. Green Cross Corp

            18.3.16.1. Overview

            18.3.16.2. Product Portfolio

            18.3.16.3. Analyst Commentary

            18.3.16.4. Key Financials

            18.3.16.5. Recent Developments

            18.3.16.6. Sales Footprint

            18.3.16.7. Strategy Overview

                18.3.16.7.1. Marketing Strategy

                18.3.16.7.2. Product Strategy

                18.3.16.7.3. Channel Strategy

        18.3.17. Jiangsu Hengrui Medicine Co., Ltd

            18.3.17.1. Overview

            18.3.17.2. Product Portfolio

            18.3.17.3. Analyst Commentary

            18.3.17.4. Key Financials

            18.3.17.5. Recent Developments

            18.3.17.6. Sales Footprint

            18.3.17.7. Strategy Overview

                18.3.17.7.1. Marketing Strategy

                18.3.17.7.2. Product Strategy

                18.3.17.7.3. Channel Strategy

19. Assumptions and Acronyms Used

20. Research Methodology

Table 01: Global Market Size (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel

Table 02: Global Market Size (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Region

Table 03: North America Market Size (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel

Table 04: North America Market Size (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country

Table 05: Latin America Market Size (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel

Table 06: Latin America Market Size (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country

Table 07: Europe Market Size (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel

Table 08: Europe Market Size (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country

Table 09: South Asia Market Size (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel

Table 10: South Asia Market Size (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country

Table 11: East Asia Market Size (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel

Table 12: East Asia Market Size (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country

Table 13: Oceania Market Size (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel

Table 14: Oceania Market Size (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country

Table 15: Middle East and Africa Market Size (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Distribution Channel

Table 16: Middle East and Africa Market Size (US$ Mn) Analysis 2018-2022 and Forecast 2023-2033, By Country

※参考情報 ペグフィルグラスチムバイオシミラーは、ペグフィルグラスチムという生物学製剤に類似した製品です。ペグフィルグラスチムは、白血球の一種である好中球の生成を促進するために使用されます。特に、化学療法に伴う好中球の減少に対する予防策として用いられ、骨髄抑制を軽減し、感染のリスクを低下させる役割があります。 ペグフィルグラスチムは、主にがん治療を受ける患者に対して処方されます。化学療法の副作用として白血球数が減少し、感染のリスクが高まることがあるため、これを防ぐ目的で使用されます。ペグフィルグラスチムは、投与後に持続的に作用することが特徴で、通常は1回の注射で数日から数週間にわたって効果が持続します。 ペグフィルグラスチムバイオシミラーは、オリジナルのペグフィルグラスチムと同等の品質であることが求められます。バイオシミラーは、オリジナルの生物学製剤と比較して、有効性や安全性が同等であることを示さなければなりません。これにより、患者に対しても同じ治療効果が期待され、医療費の削減にも寄与します。 種類としては、ペグフィルグラスチムを含むバイオシミラーは、幾つかの製品が市場に登場しています。これらの製品は、基本的にオリジナル薬と同様の分子メカニズムで作用しますが、製造プロセスや成分に微細な違いがある場合があります。各製品の特性や副作用については、製造元によって異なることがあるため、患者や医療従事者は事前に十分な情報を得て選択する必要があります。 用途としては、ペグフィルグラスチムバイオシミラーは主にがん治療を受けている患者に用いられますが、これは化学療法に伴う好中球減少症の予防だけに限られません。最近の研究では、他の疾患における好中球の役割や、好中球数を増加させることによる治療効果が注目されており、将来的には様々な病状に対する応用が期待されています。 関連技術としては、バイオ医薬品の製造に用いられる高度な技術が挙げられます。これには、細胞培養技術や、遺伝子工学、タンパク質精製技術などが含まれます。バイオシミラーの製造は、オリジナル製品と比較して複雑なプロセスを経るため、各社は特許や知的財産権を遵守하면서も、コストを抑える技術革新を進めています。また、製造プロセスのバリデーションや品質管理も厳密に行われ、治療薬としての信頼性を確保することが求められます。 最近では、ペグフィルグラスチムバイオシミラーの導入が進むにつれ、治療の選択肢が広がり、患者にとっての負担軽減が期待されています。個別化医療の進展に伴い、患者一人ひとりに合った治療法の選択が可能になることにより、より良い医療環境が整うことが目指されています。 総じて、ペグフィルグラスチムバイオシミラーは、がん治療において重要な役割を果たす生物学製剤であり、今後もその利用が広がると考えられています。医療現場における選択肢が増えることで、患者のQOL（クオリティ・オブ・ライフ）向上につながることが期待されています。

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/